series-a
Stage
1
Investors
About
Nflection is a clinical-stage biopharmaceutical company developing first-in-class MEK inhibitors for the topical treatment of neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks.
Explore Nflection's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.